AquaBounty Technologies, Inc. (NASDAQ:AQB) Short Interest Up 452.6% in December

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 423,300 shares, a growth of 452.6% from the December 15th total of 76,600 shares. Based on an average daily volume of 425,500 shares, the short-interest ratio is currently 1.0 days. Approximately 11.7% of the shares of the company are sold short.

AquaBounty Technologies Price Performance

NASDAQ:AQB traded down $0.04 during trading hours on Monday, hitting $0.74. The company’s stock had a trading volume of 121,412 shares, compared to its average volume of 439,162. AquaBounty Technologies has a 52-week low of $0.47 and a 52-week high of $2.79. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.98 and a current ratio of 3.02. The business’s 50-day moving average is $0.85 and its two-hundred day moving average is $1.14. The company has a market capitalization of $2.84 million, a PE ratio of -0.04 and a beta of 1.17.

AquaBounty Technologies (NASDAQ:AQB) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.88) EPS for the quarter, hitting analysts’ consensus estimates of ($0.88). The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.10 million. AquaBounty Technologies had a negative return on equity of 18.20% and a negative net margin of 5,842.69%. During the same quarter last year, the business posted ($1.60) EPS. As a group, research analysts anticipate that AquaBounty Technologies will post -4.86 EPS for the current fiscal year.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.